NEW YORK (dpa-AFX) - The Canadian bank RBC has left its rating for Evotec at "Sector Perform" with a target price of 18.60 euros following the resignation of the CEO and the confirmed annual outlook. The surprising departure of Werner Lanthaler is likely to be negatively received by the markets, analyst Charles Weston wrote in a study published on Thursday. Fortunately, the drug researcher has long been known for the fact that the company management is available to investors and analysts during earnings discussions and the frequent capital market days. In this respect, he believes that the company's business is in safe hands while a new CEO is being sought./edh/gl

Publication of the original study: 03.01.2024 / 17:35 / EST First distribution of the original study: 04.01.2024 / 00:45 / EST

-----------------------

dpa-AFX Broker - the Trader News from dpa-AFX

-----------------------